| Keywords: |
signal transduction; protein kinase b; cancer chemotherapy; treatment outcome; cancer surgery; clinical trial; cancer growth; cancer risk; drug efficacy; nonhuman; conference paper; combined modality therapy; molecular genetics; antineoplastic agent; protein function; cancer prevention; breast; tumor markers, biological; aromatase inhibitor; drug screening; drug synthesis; breast neoplasms; tumor marker; cancer research; cancer hormone therapy; molecular marker; cancer inhibition; cytokine; cytokines; breast carcinoma; research; predictive value of tests; tamoxifen; interdisciplinary communication; plant extract; phytotherapy; taxane derivative; progesterone receptor; hormone; trastuzumab; genes, erbb-2; receptors, steroid; hormones; molecular markers; glucocorticoid receptor; raloxifene; receptors; receptor subtype; estrogen activity; estrogen receptor alpha; selective estrogen receptor modulator; selective estrogen receptor modulators; estrogen receptor beta; cancer; humans; prognosis; human; female; priority journal; prolactin receptor
|
